GPR55: A therapeutic target for Parkinson's disease?

Neuropharmacology

Volumn 125, Issue , 2017, Pages 319-332

  Celorrio, Marta ^a,b   Rojo Bustamante, Estefanía ^a,b   Fernández Suárez, Diana ^a,f   Sáez, Elena ^a   Estella Hermoso de Mendoza, Ander ^a   Müller, Christa E ^c   Ramírez, María J ^b,e   Oyarzábal, Julen ^a   Franco, Rafael ^a,d   Aymerich, María S ^a,b,e  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF BARCELONA   (Spain)

^e IdiSNA Navarra Institute for Health Research   (Spain)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cannabinoids; GPR55; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CANNABIDIOL; DOPAMINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MESSENGER RNA; PROBENECID; UNCLASSIFIED DRUG; 3,4 DIHYDROXYPHENYLACETIC ACID; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; ANTIPARKINSON AGENT; CALCIUM BINDING PROTEIN; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; GPR55 PROTEIN, MOUSE; HALOPERIDOL; HOMOVANILLIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOWN REGULATION; GLOBUS PALLIDUS; IN SITU HYBRIDIZATION; LIMIT OF QUANTITATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN RNA BINDING; PROTEIN TARGETING; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; ANALOGS AND DERIVATIVES; ANIMAL; BASAL GANGLION; C57BL MOUSE; CATALEPSY; DRUG EFFECT; METABOLISM; NERVE CELL; PARKINSONISM; PATHOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CALCIUM-BINDING PROTEINS; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; CATALEPSY; CORPUS STRIATUM; DOPAMINE; HALOPERIDOL; HOMOVANILLIC ACID; MALE; MICE, INBRED C57BL; MICROFILAMENT PROTEINS; NEURONS; PARKINSONIAN DISORDERS; RECEPTORS, CANNABINOID; RNA, MESSENGER;

EID: 85027488482     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2017.08.017     Document Type: Article

References (54)

1. Aymerich, M.S., Rojo-Bustamante, E., Molina, C., Celorrio, M., Sánchez-Arias, J.A., Franco, R., Neuroprotective effect of JZL184 in MPP+-treated SH-SY5Y cells through CB2 receptors. Mol. Neurobiol. 53 (2016), 2312–2319, 10.1007/s12035-015-9213-3.
2. Baker, D., Pryce, G., Davies, W.L., Hiley, C.R., In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci., 2006, 10.1016/j.tips.2005.11.003.
3. Bjursell, M., Ryberg, E., Wu, T., Greasley, P.J., Bohlooly, Y.,M., Hjorth, S., Deletion of Gpr55 results in subtle effects on energy metabolism, motor activity and thermal pain sensation. PLoS One, 11, 2016, e0167965, 10.1371/journal.pone.0167965.
4. Carroll, C.B., Bain, P.G., Teare, L., Bch, B.M., Liu, X., Joint, C., Wroath, C., Parkin, S.G., Bch, B.M., Fox, P., Bch, B.M., Wright, D., Hobart, J., Zajicek, J.P., Cannabis for dyskinesia in Parkinson disease A randomized double-blind crossover study. Neurology 63 (2004), 1245–1250, 10.1212/01.WNL.0000140288.48796.8E.
5. Celorrio, M., Fernández-Suárez, D., Rojo-Bustamante, E., Echeverry-Alzate, V., Ramírez, M.J., Hillard, C.J., López-Moreno, J.A., Maldonado, R., Oyarzábal, J., Franco, R., Aymerich, M.S., Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease. Brain. Behav. Immun. 57 (2016), 94–105, 10.1016/j.bbi.2016.06.010.
6. Cherif, H., Argaw, A., Cécyre, B., Bouchard, A., Gagnon, J., Javadi, P., Desgent, S., Mackie, K., Bouchard, J.-F., Role of GPR55 during axon growth and target innervation. eNeuro, 2, 2015, 10.1523/ENEURO.0011-15.2015.
7. Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38 (2003), 223–232.
8. Drøjdahl, N., Nielsen, H.H., Gardi, J.E., Wree, A., Peterson, A.C., Nyengaard, J.R., Eyer, J., Finsen, B., Axonal plasticity elicits long-term changes in oligodendroglia and myelinated fibers. Glia 58 (2010), 29–42, 10.1002/glia.20897.
9. Esposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V., Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br. J. Pharmacol. 151 (2007), 1272–1279, 10.1038/sj.bjp.0707337.
10. Fernández-Suárez, D., Celorrio, M., Riezu-Boj, J.I., Ugarte, A., Pacheco, R., González, H., Oyarzabal, J., Hillard, C.J., Franco, R., Aymerich, M.S., Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. Neurobiol. Aging 35 (2014), 2603–2616, 10.1016/j.neurobiolaging.2014.05.021.
11. García-arencibia, M., González, S., Lago, E. De, Ramos, J.A., Mechoulam, R., Fernández-ruiz, J., Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson â€TM s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 1134 (2006), 162–170, 10.1016/j.brainres.2006.11.063.
12. Goñi-Allo, B., Ramos, M., Herv'as, I., Lasheras, B., Aguirre, N., Studies on striatal neurotoxicity caused by the 3,4-methylenedioxymethamphetamine/malonate combination: implications for serotonin/dopamine interactions. J. Psychopharmacol. 20 (2006), 245–256, 10.1177/0269881106063264.
13. Greco, B., Lopez, S., van der Putten, H., Flor, P.J., Amalric, M., Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 332 (2010), 1064–1071, 10.1124/jpet.109.162115.
14. Gundersen, H.J., Jensen, E.B., The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147 (1987), 229–263.
15. Henstridge, C.M., Balenga, N.A.B., Kargl, J., Andradas, C., Brown, A.J., Irving, A., Sanchez, C., Waldhoer, M., Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol. Endocrinol. 25 (2011), 1835–1848, 10.1210/me.2011-1197.
16. Henstridge, C.M., Balenga, N. a B., Ford, L. a, Ross, R. a, Waldhoer, M., Irving, A.J., The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation. FASEB J. 23 (2009), 183–193, 10.1096/fj.08-108670.
17. Iuvone, T., Esposito, G., De Filippis, D., Scuderi, C., Steardo, L., Cannabidiol: a promising drug for neurodegenerative disorders?. CNS Neurosci. Ther. 15 (2009), 65–75, 10.1111/j.1755-5949.2008.00065.x.
18. Johns, D.G., Behm, D.J., Walker, D.J., Ao, Z., Shapland, E.M., Daniels, D.A., Riddick, M., Dowell, S., Staton, P.C., Green, P., Shabon, U., Bao, W., Aiyar, N., Yue, T.-L., Brown, A.J., Morrison, A.D., Douglas, S.A., The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152 (2007), 825–831, 10.1038/sj.bjp.0707419.
19. Kallendrusch, S., Kremzow, S., Nowicki, M., Grabiec, U., Winkelmann, R., Benz, A., Kraft, R., Bechmann, I., Dehghani, F., Koch, M., The G protein-coupled receptor 55 ligand l -α-Lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion. Glia 61 (2013), 1822–1831, 10.1002/glia.22560.
20. Kreitzer, A.C., Malenka, R.C., Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 445 (2007), 643–647, 10.1038/nature05506.
21. Krohn, R.M., Parsons, S.A., Fichna, J., Patel, K.D., Yates, R.M., Sharkey, K.A., Storr, M.A., Abnormal cannabidiol attenuates experimental colitis in mice, promotes wound healing and inhibits neutrophil recruitment. J. Inflamm., 13, 2016, 21, 10.1186/s12950-016-0129-0.
22. Laprairie, R.B., Bagher, A.M., Kelly, M.E.M., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172 (2015), 4790–4805, 10.1111/bph.13250.
23. Larsen, J.O., Gundersen, H.J.G., Nielsen, J., Global spatial sampling with isotropic virtual planes: estimators of length density and total length in thick, arbitrarily orientated sections. J. Microsc. 191 (1998), 238–248, 10.1046/j.1365-2818.1998.00365.x.
24. Lastres-Becker, I., Molina-Holgado, F., Ramos, J.A., Mechoulam, R., Fernandez-Ruiz, J., Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. 19 (2005), 96–107 doi:S0969-9961(04)00282-7 [pii]10.1016/j.nbd.2004.11.009.
25. Lau, Y.S., Trobough, K.L., Crampton, J.M., Wilson, J.A., Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21 (1990), 181–187.
26. Lauckner, J.E., Jensen, J.B., Chen, H.-Y., Lu, H.-C., Hille, B., Mackie, K., GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 2699–2704, 10.1073/pnas.0711278105.
27. Little, P.J., Compton, D.R., Johnson, M.R., Melvin, L.S., Martin, B.R., Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J. Pharmacol. Exp. Ther. 247 (1988), 1046–1051.
28. Marichal-Cancino, B.A., Sánchez-Fuentes, A., Méndez-Díaz, M., Ruiz-Contreras, A.E., Prospéro-García, O., Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm. Behav. Pharmacol. 27 (2016), 393–396, 10.1097/FBP.0000000000000185.
29. McKillop, A.M., Moran, B.M., Abdel-Wahab, Y.H.A., Flatt, P.R., Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice. Br. J. Pharmacol. 170 (2013), 978–990, 10.1111/bph.12356.
30. McKillop, A.M., Moran, B.M., Abdel-Wahab, Y.H.A., Gormley, N.M., Flatt, P.R., Metabolic effects of orally administered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. Diabetologia, 2016, 10.1007/s00125-016-4108-z.
31. McPartland, J.M., Duncan, M., Di Marzo, V., Pertwee, R.G., Are cannabidiol and ??9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol. 172 (2015), 737–753, 10.1111/bph.12944.
32. Meadows, A., Lee, J., Wu, C.-S., Wei, Q., Pradhan, G., Yafi, M., Lu, H.-C., Sun, Y., Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. Int. J. Obes. 40 (2015), 417–424, 10.1038/ijo.2015.209.
33. More, S.V., Choi, D.-K., Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol. Neurodegener., 10, 2015, 17, 10.1186/s13024-015-0012-0.
34. Neustadt, B.R., Liu, H., Hao, J., Greenlee, W.J., Stamford, A.W., Foster, C., Arik, L., Lachowicz, J., Zhang, H., Bertorelli, R., Fredduzzi, S., Varty, G., Cohen-Williams, M., Ng, K., Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorg. Med. Chem. Lett. 19 (2009), 967–971, 10.1016/j.bmcl.2008.11.075.
35. Niswender, C.M., Johnson, K.A., Weaver, C.D., Jones, C.K., Xiang, Z., Luo, Q., Rodriguez, A.L., Marlo, J.E., de Paulis, T., Thompson, A.D., Days, E.L., Nalywajko, T., Austin, C.A., Williams, M.B., Ayala, J.E., Williams, R., Lindsley, C.W., Conn, P.J., Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 74 (2008), 1345–1358, 10.1124/mol.108.049551.
36. Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., Sugiura, T., Identification of GPR55 as a Lysophosphatidylinositol Receptor. 2007, 10.1016/j.bbrc.2007.08.078.
37. Paxinos, G., Franklin, K.B., The Mouse Brain in Sterotaxic Coordinates. 2001, Academic Press.
38. Petitet, F., Donlan, M., Michel, A., GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem. Biol. Drug Des., 2006, 10.1111/j.1747-0285.2006.00370.x.
39. Petroske, E., Meredith, G.E., Callen, S., Totterdell, S., Lau, Y.S., Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 106 (2001), 589–601 doi:S0306-4522(01)00295-0 [pii].
40. Pietr, M., Kozela, E., Levy, R., Rimmerman, N., Lin, Y.H., Stella, N., Vogel, Z., Juknat, A., Differential changes in GPR55 during microglial cell activation. FEBS Lett. 583 (2009), 2071–2076, 10.1016/j.febslet.2009.05.028.
41. Price, D.A., Martinez, A.A., Seillier, A., Koek, W., Acosta, Y., Fernandez, E., Strong, R., Lutz, B., Marsicano, G., Roberts, J.L., Giuffrida, A., WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur. J. Neurosci. 29 (2009), 2177–2186, 10.1111/j.1460-9568.2009.06764.x.
42. Rabal, O., Sánchez-Arias, J.A., Cuadrado-Tejedor, M., de Miguel, I., Pérez-González, M., García-Barroso, C., Ugarte, A., Estella-Hermoso de Mendoza, A., Sáez, E., Espelosin, M., Ursua, S., Haizhong, T., Wei, W., Musheng, X., Garcia-Osta, A., Oyarzabal, J., Design, synthesis, and biological evaluation of first-in-class dual acting histone deacetylases (HDACs) and phosphodiesterase 5 (PDE5) inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 59 (2016), 8967–9004, 10.1021/acs.jmedchem.6b00908.
43. Ross, R.A., The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 30 (2009), 156–163, 10.1016/j.tips.2008.12.004.
44. Russo, E.B., Burnett, A., Hall, B., Parker, K.K., Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 30 (2005), 1037–1043, 10.1007/s11064-005-6978-1.
45. Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N.-O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., Greasley, P.J., The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152 (2007), 1092–1101, 10.1038/sj.bjp.0707460.
46. Sánchez-Arias, J.A., Rabal, O., Cuadrado-Tejedor, M., de Miguel, I., Pérez-González, M., Ugarte, A., Sáez, E., Espelosin, M., Ursua, S., Haizhong, T., Wei, W., Musheng, X., Garcia-Osta, A., Oyarzabal, J., Impact of scaffold exploration on novel dual-acting histone deacetylases and phosphodiesterase 5 inhibitors for the treatment of Alzheimer's disease. ACS Chem. Neurosci., 2016, 6b00370, 10.1021/acschemneuro.6b00370.
47. Sawzdargo, M., Nguyen, T., Lee, D.K., Lynch, K.R., Cheng, R., Heng, H.H.Q., George, S.R., O'Dowd, B.F., Identification and cloning of three novel human G protein-coupled receptor genes GPR52, ΨGPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res. 64 (1999), 193–198, 10.1016/S0169-328X(98)00277-0.
48. Schicho, R., Bashashati, M., Bawa, M., McHugh, D., Saur, D., Hu, H.M., Zimmer, A., Lutz, B., MacKie, K., Bradshaw, H.B., McCafferty, D.M., Sharkey, K.A., Storr, M., The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm. Bowel Dis. 17 (2011), 1651–1664, 10.1002/ibd.21538.
49. Schober, A., Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318 (2004), 215–224, 10.1007/s00441-004-0938-y.
50. Shook, B.C., Rassnick, S., Osborne, M.C., Davis, S., Westover, L., Boulet, J., Hall, D., Rupert, K.C., Heintzelman, G.R., Hansen, K., Chakravarty, D., Bullington, J.L., Russell, R., Branum, S., Wells, K.M., Damon, S., Youells, S., Li, X., Beauchamp, D.A., Palmer, D., Reyes, M., Demarest, K., Tang, Y., Rhodes, K., Jackson, P.F., In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease. J. Med. Chem. 53 (2010), 8104–8115, 10.1021/jm100971t.
51. Staton, P.C., Hatcher, J.P., Walker, D.J., Morrison, A.D., Shapland, E.M., Hughes, J.P., Chong, E., Mander, P.K., Green, P.J., Billinton, A., Fulleylove, M., Lancaster, H.C., Smith, J.C., Bailey, L.T., Wise, A., Brown, A.J., Richardson, J.C., Chessell, I.P., The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139 (2008), 225–236, 10.1016/j.pain.2008.04.006.
52. Su, E.N., Kelly, M.E., Cringle, S.J., Yu, D.Y., Role of endothelium in abnormal cannabidiol-induced vasoactivity in retinal arterioles. Investig. Ophthalmol. Vis. Sci. 56 (2015), 4029–4037, 10.1167/iovs.14-14879.
53. Wiley, J.L., Marusich, J.A., Huffman, J.W., Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 97 (2014), 55–63, 10.1016/j.lfs.2013.09.011.
54. Wu, C.S., Chen, H., Sun, H., Zhu, J., Jew, C.P., Wager-Miller, J., Straiker, A., Spencer, C., Bradshaw, H., Mackie, K., Lu, H.C., GPR55, a G-protein coupled receptor for lysophosphatidylinositol, plays a role in motor coordination. PLoS One, 8, 2013, e60314, 10.1371/journal.pone.0060314PONE-D-12-30016 [pii].